Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable ...

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against ...

Pfizer also beat analyst expectations for first-quarter earnings as it benefited from cost-saving efforts, although it fell short of Wall Street’s revenue estimate, as sales of its COVID-19 ...

All the COVID-19 vaccines used in the U.S. train the body to fight the coronavirus by recognizing its outer coating, the ...

The COVID vaccines used in the U.S. train the body to recognize the tell-tale spike protein on the SARS-CoV2 virus. Unlike ...

Pfizer Q1 EPS beat at $0.92 vs. $0.67 estimate, but sales dipped 8% YoY to $13.71 billion, below $13.95 billion forecast. Paxlovid sales plunged 75%, while Vyndaqel jumped 33% and Comirnaty rose ...

Pfizer said Paxlovid sales fell $1.5 billion, or 75%, to roughly $500 million, partly due to lower COVID-19 infections in the U.S. and a drop in purchases by governments. On the plus side ...

Additionally, Comirnaty, Pfizer’s Covid-19 vaccine, brought in $565 million in sales during the quarter, significantly higher than the $354 million revenue recorded in the same quarter last year.